November 05, 2025

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

Dana-Farber

October 31, 2025

FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL

The FDA has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL)—including diffu...

The ASCO Post

October 31, 2025

Combination Therapies for Diffuse Large B-Cell Lymphoma: 5-Year Outcomes of the POLARIX Trial

As reported in the Journal of Clinical Oncology by Morschhauser et al, the 5-year findings of the POLARIX trial showed a continued benefit with polatuzumab vedotin plus rituximab, cyclophosphamide, do...

The ASCO Post

October 30, 2025

Variation in PSA Levels in Annual Testing Among Individuals Without a Prostate Cancer Diagnosis

In a study reported in JAMA Oncology, Pickersgill et al found that individuals without prostate cancer undergoing annual prostate-specific antigen (PSA) testing often exhibited a PSA level below biops...

The ASCO Post

October 29, 2025

KIM-1 in Kidney Cancer Study Presented by Vincent Xu, MD

Dana-Farber Cancer Institute's D. Wenxin (Vincent) Xu shares research suggesting a blood test measuring levels of the KIM-1 biomarker could help assess the burden of disease in advanced kidney cancer and predict outcomes during first-line treatment.

Dana-Farber

October 29, 2025

Linking Neurocognitive Outcomes and Advanced Techniques in Awake Glioma Surgery

Glioma surgery in eloquent brain regions remains one of the greatest challenges in neurosurgery, demanding a balance between oncologic control and preservation of function.

Baptist Health South Florida

October 29, 2025

LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility

Large language models (LLMs) can be trained to understand how each patient’s somatic mutations impact their cancer prognosis and possible response to therapy, according to a presentation at the AACR S...

The ASCO Post

October 29, 2025

Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction

Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpre...

The ASCO Post

October 29, 2025

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...

The ASCO Post